STK24

Serine/threonine-protein kinase 24 · Q9Y6E0 · STK24 on Sugi Atlas →

5,093 patent compounds predicted against STK24, 3,783 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1076004	0.69	2/20
SCHEMBL1680968	0.51	2/20
SCHEMBL1681347	0.50	2/20
SCHEMBL1074976	0.49	2/20
SCHEMBL1075083	0.49	2/20
Hydrochloric Acid (SCHEMBL1075124)	0.48	2/20
Hydrochloric Acid (SCHEMBL1075617)	0.48	2/20
SCHEMBL1074134	0.41	2/20
SCHEMBL1074138	0.41	2/20
SCHEMBL1075002	0.41	2/20
Hydrochloric Acid (SCHEMBL1073441)	0.41	2/20
SCHEMBL1075045	0.39	2/20
SCHEMBL1075467	0.38	2/20
SCHEMBL415996	0.38	2/20
Trifluoroacetic Acid (SCHEMBL1071674)	0.37	2/20
SCHEMBL1076209	0.37	2/20
SCHEMBL1073905	0.37	2/20
Trifluoroacetic Acid (SCHEMBL1072466)	0.36	2/20
Trifluoroacetic Acid (SCHEMBL1075014)	0.36	2/20
SCHEMBL1075946	0.36	2/20

Clinical trials — most relevant to STK24 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)	PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Exercise in Type 1 Diabetes Mellitus	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a STK24 binder may also engage these)

Protein	Name	Similarity
Q99KH8	—	1.000	Q99KH8 →
Q99JT2	—	1.000	Q99JT2 →
B0LT89	—	1.000	B0LT89 →
STK26	Serine/threonine-protein kinase 26	1.000	landscape →
STK25	Serine/threonine-protein kinase 25	1.000	landscape →
Q3SWY6	—	0.999	Q3SWY6 →
Q9Z2W1	—	0.998	Q9Z2W1 →
PAK3	Serine/threonine-protein kinase PAK 3	0.994	landscape →
Q4KSH7	—	0.994	Q4KSH7 →
MAP2K7	Dual specificity mitogen-activated protein kinase kinase 7	0.994	landscape →
P35465	—	0.993	P35465 →
Q08E52	—	0.992	Q08E52 →
Q8AXB4	—	0.992	Q8AXB4 →
O88643	—	0.992	O88643 →
PAK2	Serine/threonine-protein kinase PAK 2	0.992	landscape →
Q7YQL4	—	0.991	Q7YQL4 →
Q9NB31	—	0.991	Q9NB31 →
P13234	—	0.991	P13234 →
O35832	—	0.990	O35832 →
Q7YQL3	—	0.990	Q7YQL3 →
Q8CIN4	—	0.989	Q8CIN4 →
A4K2M3	—	0.989	A4K2M3 →
O35831	—	0.988	O35831 →
Q04899	—	0.988	Q04899 →
O08875	—	0.988	O08875 →
C0RW22	—	0.988	C0RW22 →
Q64303	—	0.988	Q64303 →
O61125	—	0.988	O61125 →
P08458	—	0.988	P08458 →
A4K2Y1	—	0.988	A4K2Y1 →